Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Hybrid CDMO-gene therapy developer Forge launches with $40M

Garabedian-backed start-up Forge Biologics to take gene therapy for Krabbe disease into clinic

With $40 million from an investor group led by Chris Garabedian’s PXV fund, newly launched Forge Biologics is building a hybrid company that will offer CDMO services to gene therapy companies while also developing its own pipeline, including a lead program for Krabbe disease.

Housed in an existing facility called the Hearth in Columbus, Ohio, Forge is adding capacity and technology that the company believes will allow it to provide cGMP manufacturing services

Read the full 723 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers